Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.
Twelve years on from the World Health Organization formally raising the alarm, antimicrobial resistance continues to grow, and despite numerous public and private incentives and initiatives, the pipeline of antibiotics in development is thinner than ever.
Shionogi & Co. Ltd. has disclosed heterocyclic derivatives characterized as reverse transcriptase/ribonuclease H (HIV-1) inhibitors for potential use in the treatment of HIV infection.
Atea Pharmaceuticals Inc. recently presented preclinical data on two of its compounds, AT-2490 and AT-587, which have shown promising antiviral potential for treating hepatitis E virus infection.
Aiming to develop a vaccine candidate against human adenovirus-55 (HAdV-55) infections, researchers from the First Affiliated Hospital of Guangzhou Medical University (China) and collaborators have generated a replication-incompetent rAd55-5E4.
HIV-1 persistence in latent reservoirs of T lymphoid and myeloid origin is a major barrier for the cure of the disease, with complex and multifactorial mechanisms behind HIV-1 latency; thus, investigating these mechanisms is key for future targeted HIV therapies.
Gilead Sciences Inc.’s integrase strand transfer inhibitor (INSTI) GS-3242 is in early clinical development for HIV infection (NCT07001319). The company presented nonclinical data on the candidate at the recent CROI meeting in Denver.
CARB-X is awarding $1.2 million to the Andrew G. Myers research group at Harvard University to develop enhanced antibiotics that target multidrug-resistant gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia and bloodstream infections.
In what it says could be the largest disclosed patent settlement in the pharmaceutical industry, Roivant Sciences Ltd. has reached a potential $2.25 billion settlement with Moderna Inc. over the use of its lipid nanoparticle delivery technology in the Spikevax COVID-19 vaccine.
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported. Because cancer cells and HIV-infected cells have similar features, researchers from City of Hope National Medical Center tested the anit-HIV effects of a small-molecule compound, AOH-1996, that targets caPCNA.
RSS
